/C O R R E C T I O N - DarioHealth Corp./
Key Highlights
- ➤Q3 revenue $5.3 million, up 6% year-over-year and 3% sequentially
- ➤Operating expenses fell 10% year-over-year; operating loss improved 15%
- ➤Contracted and late-stage ARR reached $13.1 million across more than 180 accounts
- ➤New Jersey health plan signed, representing approximately 1.5 million covered lives
- ➤Cash, cash equivalents and short-term deposits totaled $31.2 million at September 30
Expert Statements
Erez Raphael, Chief Executive Officer of DarioHealth
“In the second quarter of 2026, we described how Dario's business model is designed to support growth. We believe that our third quarter of 2026 shows that model is working, with multi-condition expansion within existing accounts and new health plan agreements through our channel partners.”
Erez Raphael, Chief Executive Officer of DarioHealth
“At the same time, the market is moving toward the integrated platform we have spent more than a decade building. For years, the industry treated consumer health and payer-funded chronic care as two different businesses. We believe they are becoming one, and Dario sits exactly where they meet. Payers are moving from buying programs around a single therapy to buying a multi-condition integrated platform, as well as the therapy delivered inside a managed program, and we see that as a meaningful expansion of what Dario can do for payers and their members.”
Lara Dodo, Chief Operating Officer of DarioHealth
“We are adding large health plans through our channel partners and expanding inside the accounts we already serve.”
Lara Dodo, Chief Operating Officer of DarioHealth
“The rapid adoption of our new solutions like Dario Women reflects growing customer interest for more personalized, integrated care. We are meeting that demand with solutions that address interconnected chronic conditions and are demonstrated to deliver better health outcomes.”
Chen Franco-Yehuda, Chief Financial Officer of DarioHealth
“We grew revenue 6% year-over-year while reducing our operating expenses by 10% and our operating loss by 15%. Our B2B2C gross margin has remained strong, and we are focused on scaling that model.”
Chen Franco-Yehuda, Chief Financial Officer of DarioHealth
“With $31.2 million in cash, cash equivalents and short-term deposits, we believe we have the resources to execute on our priorities.”
In the news release, DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction, issued 12-Nov-2026 by DarioHealth Corp. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction
* Third quarter 2026 revenue increased 6% year-over-year and 3% sequentially to $5.3 million * GAAP gross margin was 59%, compared to 60% in the third quarter of 2025; non-GAAP business-to-business-to-consumer ("B2B2C") gross margin remained at approximately 80% for the 11th consecutive quarter * Revenue expected to accelerate at the end of 2026 and into 2027, driven primarily by the conversion of committed annual recurring revenue ("ARR"), including new enterprise customers and multi-condition expansions, such as Dario Women™ and Dario Sleep * Expanding payer relationships from digital health behavior programming to integrated clinical care and medication management: working with a national health plan customer to bring GLP-1 therapy delivery into its member marketplace * Signed one of New Jersey's largest health plans, representing 1.5 million covered lives, the third state health plan signed through the Amwell channel partnership in the past 12 months * Operating loss decreased by 15% year-over-year while operating expenses declined by 10% year-over-year * Cash, cash equivalents and short-term deposits totaled $31.2 million as of September 30, 2026 * More than 180 signed accounts across employers and health plans, with contracted and late-stage ARR of $13.1 million, more than 80% of it relates to multi-condition opportunities * Conference call today, November 12, 2026 at 8:30 am ET NEW YORK, Nov. 12, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the third quarter ended September 30, 2026. This press release corrects certain information in the financial tables, including the reconciliations of GAAP to non-GAAP financial measures, contained in the Company's press release originally issued on November 12, 2026. The corrected financial tables are included below.
Get started
Create a free account to read the full story.